Click here for printer friendly page
Drakeman and Pauwels join Advent Venture Partners27/06/2007. Source: AltAssets. 
 Advent Venture Partners has announced the appointment of Don Drakeman and Rudi Pauwels as Venture Partners in the life sciences team. They are to work with Advent Ventures’ portfolio companies to help progress their potential and with the investment team to source, assess and manage new investments. Don Drakeman will be based in Princeton, New Jersey and Rudi Pauwels will be based in Lausanne, Switzerland.
Don Drakeman PhD is an entrepreneur and executive who has co-founded two biotechnology companies: Medarex, Inc. and Genmab A/S. Under his leadership as president and CEO, Medarex raised a billion dollars, formed alliances with several major pharmaceutical companies, advanced many therapeutic products into clinical development and spun-off Genmab.
Rudi Pauwels PhD is a pharmaceutical scientist and biotechnology entrepreneur. He has founded several European Biotechnology Companies, including Tibotec, Virco, and Galapagos. As founder, CEO and CSO, he was responsible for advancing the anti-HIV pipeline at Tibotec-Virco from research concepts to Phase III clinical trials. The company was acquired by Johnson and Johnson in 2002. The first of these anti-HIV drugs, the protease inhibitor Prezista, recently obtained FDA and EMEA approval, and two further drugs are at an advanced clinical development stage.
Commenting on these appointments Dr Raj Parekh, general partner at Advent Ventures, said, ‘We are delighted to have attracted two such outstanding individuals to our team. With their judgement and experience in discovering breakthrough medicines and in building successful biotechnology companies to exploit innovative science, I am confident that both Don and Rudi will make major contributions to creating significant value in our portfolio companies. We welcome them to our team and look forward to working with them.’
Advent Ventures is a UK-based technology venture capital house. Established in 1981 it invests in both the life science and the technology sectors. Advent Ventures has £500m under management from institutional investors across Europe and the USA. It has backed around 60 life science companies of which, to date, 22 have obtained public listings and a further 9 companies have been sold including PowderMed and KuDOS Pharmaceuticals.
Copyright © 2007 AltAssets
|
